Andere Sprachen Ildong Pharmaceutical Co., Ltd.

Aktien

A249420

KR7249420001

A249420

Schlusskurs Korea S.E. Andere Börsenplätze 00:00:00 10.05.2024			% 5 Tage	% 1. Jan.
15 440 ^KRW	-1,40 %		-0,77 %	-14,98 %

2023	Ildong Pharmaceutical Co. Ltd. meldet Ergebnis für das erste Quartal bis zum 31. März 2023	CI
2023	Ildong Pharmaceutical Co., Ltd. reicht bei der MFDS einen Antrag auf ein neues Arzneimittel für die Indikation SARS-CoV-2-Infektion ein, der von der MFDS zur Prüfung angenommen wurde	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Il Dong Pharmaceutical Eyes Approval for to Manufacture Japan's COVID-19 Treatment in South Korea	29.12.
Il Dong Pharmaceutical Introduces New R&D Unit Yunovia	06.11.
Ildong Pharmaceutical Co., Ltd. announced that it has received KRW 30 billion in funding	20.10.23
Ildong Pharmaceutical Co., Ltd. announced that it expects to receive KRW 30 billion in funding	18.10.23
Ildong Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	15.05.23
Il Dong's Application for Shionogi's COVID Oral Medication Accepted for Review in South Korea	04.01.23
Ildong Pharmaceutical Co., Ltd. Files a New Drug Application with the MFDS for the Indication of SARS-CoV-2 Infection, and This Application Has Been Accepted for Review by MFDS	04.01.23
Shionogi JV Sub-licenses COVID-19 Drug to South Korea's Il Dong Pharmaceutical	19.09.22
Twist Bioscience, Ildong Pharmaceutical Partner to Discover Antibodies for Immuno-Oncology	30.06.22
Twist Bioscience Corporation and Ildong Pharmaceutical Enter into Collaboration to Enhance Antibody Discovery for Applications in Immuno-Oncology	30.06.22
Ildong Pharmaceutical : Interim Report on Business Performance (Fair Disclosure)	17.02.22
South Korean Pharmaceutical Firms Rush to Develop COVID-19 Oral Pills	29.12.21
Il Dong Pharmaceutical Starts Clinical Trial of COVID-19 Drug	29.11.21
Ildong Pharmaceutical : starts Phase 1 study of new diabetes therapy in Germany	01.07.21
Ildong Pharmaceutical Starts Phase 1 Study of New Diabetes Therapy in Germany	01.07.21
Ildong Pharmaceutical Co., Ltd. announced that it has received KRW 100 billion in funding	28.01.21
Ildong Pharmaceutical Co., Ltd. announced that it expects to receive KRW 100 billion in funding	18.01.21
Evotec SE and Ildong to Collaborate with Development Projects on Indigo Platform	31.03.20
Ildong Pharmaceutical Co., Ltd. Enters into Co-Promotion Agreement with GSK Consumer Healthcare SA	05.12.19
Ildong Holdings Co., Ltd. acquired 5.18% stake in Ildong Pharmaceutical Co., Ltd. from Il-dong Foods Co. Ltd. and Lee, Keumki for KRW 22.4 billion.	27.02.19

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Ildong Pharmaceutical Co., Ltd.

Aktien

A249420

KR7249420001

A249420

Andere Sprachen

Filter